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Abstract
Inflammatory bowel diseases (IBD) are chronic disabling gastrointestinal disorders impacting
every aspect of the affected individual's life and account for substantial costs to the health care
system and society. New epidemiological data suggest that the incidence and prevalence of the
diseases are increasing and medical therapy and disease management have changed significantly
in the last decade. An estimated 2.5–3 million people in Europe are affected by IBD, with a
direct healthcare cost of 4.6–5.6 bn Euros/year. Therefore, the aim of this review is to
describe the burden of IBD in Europe by discussing the latest epidemiological data, the
disease course and risk for surgery and hospitalization, mortality and cancer risks, as well as
the economic aspects, patients' disability and work impairment.
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The inflammatory bowel diseases (IBD), Crohn's disease
(CD) and ulcerative colitis (UC), are chronic inflammatory
disorders of the gastrointestinal tract of unknown etiology.
The diseases are thought to be the result of a disregulated
mucosal immune response to commensal gut flora in
genetically susceptible individuals. The impact of IBD on
patients' quality of life is substantial due to early onset,
fluctuating disease course and the lack of a cure. Furthermore,
CD and UC account for substantial costs to the health care
system and society. Descriptive epidemiological studies are
important for health care system leadership, as they provide
valuable information for decision making. The aim of this
review is to describe the burden of IBD in Europe by discussing
the occurrence of IBD, the risk for surgery and hospitalization,
mortality and cancer risks, as well as the patients' disability
and work impairment.2. Incidence and prevalence in Europe
The incidence and prevalence of IBD is subject to considerable
variation, both between and within geographic regions, with
IBD being more common in industrialized than in non-
industrialized countries. Traditionally, the highest occurrence
of both UC and CD is found in the developed countries of North
America1,2 and Europe. Within Europe, the highest incidence
and prevalence rates are found in Scandinavia3–15 and the
United Kingdom16–19 while the diseases remain rare in Eastern
Europe.20–22 However, the occurrence of IBD is a dynamic
process as increasing incidence rates being reported from
previously low incidence areas, including not only Asia,23 for
instance, but also Eastern Europe.24,25
The comparison of incidence and prevalence rates in IBD
across multiple studies is challenging. Detection rates and
diagnostic criteria differ between studies, just as access to
diagnostic procedures, such as endoscopy, may vary over time
and between centers. Furthermore, methods of case assess-
ment, as well as physicians' disease awareness, vary consid-
erably and complete case assessment is dependent on the
ability to identify all cases in the population. As such,
prospective population-based studies are preferable in de-
scriptive epidemiology compared to studies using secondary
data that depend on existing hospital or public health registry
systems; however such prospective population-based studies
are both expensive and time consuming, and therefore rare. It
is thus essential to bear in mind that observed differences
between regionsmight either be attributed to real differencesin environmental factors, lifestyle, and genetic susceptibility
or simply be due to differences in methodology.2.1. Incidence and prevalence rates
Incidence and prevalence rates from selected countries in
Europe are shown in Tables 1 and 2. The incidence of CD in
Europe ranges from 0.5 to 10.6 cases per 100,000 person-years
while the estimates for UC range from 0.9 to 24.3 per
100,000 person-years. The highest incidence rates are observed
in Scandinavia and the United Kingdom, while the lowest rates
are seen in southern and Eastern Europe — suggesting a
north-west/south-east gradient in IBD incidence. The European
Collaborative Study on Inflammatory Bowel Disease (EC-IBD)
assessed the north–south gradient in a prospective population-
based cohort using uniformed diagnostic criteria and case
ascertainment methods. The total incidence rates in northern
Europe were 6.3 for CD and 11.4 for UC per 100,000 person-
years, while in southern Europe they were for 3.6 and 8.0 per
100,000 person-years, respectively.26
Extrapolation of the incidence figures on the total European
population (app. 731 million in 2006,27) despite the challenges
of heterogeneous health care systems and differences in study
methodology between countries and centers, would indicate a
maximal estimate of 78,000 new cases of CD and 178,000 new
cases of UC each year — for a combined estimate of 256,000
new cases of IBD per year. Previous reviews28 have used the
population of the European Union (27 countries, approximately
500 million in 201229) which would yield 53,000 new cases of
CD and 123,000 new cases of UC each year, with a combined
estimate of 176,000 new cases of IBD each year.
The prevalence of CD in Europe varies from 1.522 to 21312
cases per 100,000 persons, whereas the prevalence of UC in
Europe varies from 2.422 to 2946 cases per 100,000 persons. As
for the incidence of IBD, the highest prevalence rates are found
in Northern Europe. Extrapolating these numbers for the total
European population indicates that there may be up to
1.6 million persons with CD and 2.1 million persons with UC in
Europe, meaning a combined total of 3.7 million persons with
IBD. Using the population of the European Union yieldsmaximal
estimates of 1.1 million persons with CD and 1.5 million
persons with UC in Europe, for a combined total of 2.6 million
persons with IBD.
Since the incidence of both CD and UC is increasing
or stable in virtually every region of the world,30 the
prevalence of IBD is expected to increase further due
to the early age of onset and lowmortality of IBD patients. The
emergence of IBD in traditionally low-prevalence regions (i.e.
Eastern Europe) will further contribute to this increase. A
Table 1 Incidence rates of CD and UC in selected populations.
Country Region Study period CD incidence (105) UC incidence (105)
Eastern Europe
Czech Republic20 North Bohemia 1978 NA 1.3
Estonia21 Tartu County 1993–1998 1.4 1.7
Hungary24 Western Hungary 2002–2006 8.9 11.9
Romania22 Nationwide 2002–2003 0.5 0.97
Southern/Central Europe
Belgium132 Liege 1993–1996 4.5 3.6
Croatia25 Primorsko-goranska County 2000–2004 6.5 4.6
Croatia133,134 Zagreb 1980–1989 0.7 1.5
France135 Northern France 2006–2007 6.7 3.4
Germany136 Oberpfalz 2004–2006 6.6 3.9
Greece137 North-western Greece 1983–2005 2.7 0.9
Italy138 Florence 1990–1992 3.4 9.6
Italy139 8 Italian cities 1989–1992 2.3 5.2
The Netherlands140 South Limburg 1991–2003 6.2 7.7
Spain141 Navarra 2001–2003 5.9 9.6
Spain142 Oviedo 2000–2002 7.5 9.1
Spain143 Madrid 2003–2005 7.3 7.1
Northern Europe
Denmark3,4 Copenhagen county 1962–1987 4.1 8.1
Denmark5 Copenhagen county 2003–2005 8.6 13.4
Denmark6 North Jutland 1978–2002 6.7 12.2
Faroe Islands7 Nationwide 1981–1988 3.6 20.3
Finland8 Tampere 1986–1999 7.2 16.5
Iceland9 Nationwide 1990–1994 5.5 16.5
Norway10,11 Southeast Norway 1990–1993 5.8 13.6
Sweden12 Stockholm county 1990–2001 8.3 NA
Sweden13,14 Örebro 1963–1987 6.1 13.1
Sweden15 Uppsala 2005–2007 NA 17.5
United Kingdom16 Derby 1991–1992 10.6 NA
United Kingdom17 North Tees 1990–1994 8.3 13.9
United Kingdom18 Cardiff 1996–2005 6.6 NA
Northern Europe26 8 Northern European cities 1991–1993 6.3 11.4
Iceland, Reykjavik 8.2 24.3
Norway, Oslo 6.9 15.6
Denmark, Copenhagen 6.6 10.0
Ireland, Dublin 5.9 14.8
UK, Leicester (nonimmigrants) 3.2 9.2
UK, Leicester (immigrants) 4.7 15.1
The Netherlands, Maastricht 7.7 13.1
Germany, Essen 3.5 4.3
France, Amiens 8.1 5.6
Southern Europe26 12 Northern European cities 1991–1993 3.6 8.0
Italy, Milan-Varese 3.2 10.0
Italy, Crema-Cremona 2.7 7.5
Italy, Reggio Emilia 4.0 7.5
Italy, Florence 2.7 8.1
Italy, Palermo, Sicily 5.8 8.5
Spain, Vigo 4.8 7.0
Spain, Sabadell 4.9 9.0
Portugal, Braga 3.7 5.5
Portugal, Almada 2.3 1.7
Greece, Northwest Greece 1.0 8.5
Greece, Heraklion, Crete 3.9 16.6
Israel, Beer Sheva 4.3 8.5
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Table 2 Prevalence rates of CD and UC in selected populations.
Country Region Study period CD prevalence (105) UC prevalence (105)
Eastern Europe
Czech Republic20 North Bohemia 1968–1978 NA 17.6
Hungary144 Veszprem Province 1991–2001 52.9 142.6
Romania22 Nationwide 2004 1.5 2.4
Southern/Central Europe
Croatia133,134 Zagreb 1989 8.3 21.4
Bosnia and Herzegovina145,146 Tuzla 2006 28.2 43.1
Italy138 Florence 1992 40 121
The Netherlands147,148 Leiden 1979–1983 48 58.4
Germany149 Tubingen 1984 54.6 24.8
Spain150 Asturias 1997 87.5 110.0
Spain151 Madrid 1988 19.8 43.4
Switzerland152 Canton of Vaud 2003–2004 100.7 105.0
Northern Europe
Denmark3,4 Copenhagen county 1987 54 161.2
Denmark6 North Jutland 2002 151 294
Faroe Islands153 Nationwide 1986 31.8 157.3
Finland8 Tampere 1986–1999 82 205
Iceland154 Nationwide 1950–1979 6 72
Sweden12 Stockholm county 2001 213 NA
Sweden13,14 Örebro 1987 146 198
United Kingdom19 Derby 1985 85 NA
United Kingdom17 North Tees 1994 144.8 243.4
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Committee (EpiCom) is investigating the East–west gra-
dient in the incidence of IBD, as well as differences in
potential environmental risk factors between Eastern and
Western Europe.31The incidence and prevalence of CD and UC is in-
creasing in Europe.
Estimated 0.3% of the European population suffers
from IBD equalling 2.5–3 million persons.3. Disease phenotype, overall disease course
and relapse rates
One of the most important parameter associated with long-
term outcomes is the disease phenotype. Current practice
guidelines advocate the use of the Montreal classification in
both CD and UC.32 The most important variables are age at
onset and disease location (terminal ileum (L1), colon (L2)
and ileocolon (L3) and upper GI (L4) as modifier), behavior
(non-stricturing non-penetrating (B1), structuring (B2) and
penetrating (B3)) and presence of perianal disease in CD and
disease extent (proctitis (E1), left-sided (E2) and extensive
(E3)) in UC. Yet, there are still limited data available on the
natural history of IBD in Europe.
In CD, the distribution of location is relatively homogeneous
and stable with the exception of the reported variance in thefrequency of the upper GI location, especially in pediatric—
versus adult-onset populations. In addition, the proportion of
isolated colonic disease is increasing in the last decade. An
example may be the recent IBSEN cohort33 with 27% of patients
with L1, 48% L2 and 23% L3 and only 2% L4 disease at
presentation. Somewhat lower rates of isolated colonic disease
were reported from Denmark (L2: 30%, 43% and 37% in 1962–
1987, 1991–1993 and 2003–2004).34 Similar data were recently
reported also from Eastern Europe (L1: 20%; L2: 35%, L3: 44%
and all L4: 2.4%)24 in 2002–2006.
Up to one-third of European patients may present with
complicated disease phenotype at diagnosis, e.g. in the IBSEN
cohort 36%, 49% and 53% of patients had presented with or
developed stricturing or penetrating disease at diagnosis or
after 5- or 10-years. In contrast, in previous cohorts by Cosnes
et al.,35 up to 70% of CD patients developed either penetrating
or stricturing disease. Similar results were published in a
Belgian study.36 45.9% of patients had a change in disease
behavior during 10 years of follow-up, from non-stricturing,
non-penetrating disease to either stricturing (27.1%) or
penetrating (29.4%) disease. In contrast, disease location
remained relatively stable during follow-up, with only
15.9% of patients exhibiting a change in disease location
during the first 10 years. The rate of perianal complica-
tion may vary between 10 and 20% at presentation.
In UC, the distribution of the disease extent at diagnosis is
variable among the different cohorts with increasing rates of
proctitis. In the IBSEN cohort37 the distribution of the disease
extent was E1 in 32%, E2 in 35% and E3 in 33%. Of the patients
initially diagnosed with proctitis, 28% had progressed during
Themajority of the patients with inflammatory diseases
in Europe experience a relapsing disease course with
20–25% of patients experiencing chronic continuous
symptoms.
Up to 30–40% of CD patients in Europe present with
complicated disease phenotype at diagnosis and a
similar proportion of patients may develop complica-
tions over the next 10–15-years of follow-up.
326 J. Burisch et al.the observation period, 10% to extensive colitis over the next
5-years. Similar distribution of the initial disease extent was
observed in a population-based cohort from Eastern Europe
(E1: 27%, E2: 51% and E3: 22%),24 while the 5-year probability
of proximal disease extension in patients with initial proctitis
or left-sided colitis was 12.7%. The rate of proctitis was more
variable in Denmark,34 with 44%, 60% and 31% at diagnosis
reported in 1962–1987, 1991–1993 and 2003–2004. Little data
are available on the relapse rates and overall disease course in
IBD from Europe. Most data were published from the Nordic
countries.
In one of the early publications, the long-term disease
course was reported in 185 CD patients followed-up regularly
between 1960 and 78 in Copenhagen, Denmark.38 About 45% of
patients werewithout clinical symptoms for all the observation
years. The disease activity was low in app. 30% of patients and
moderate-to high in app. 25%. Continuous disease activity was
observed in about 20% and intermittent symptoms were
reported in 35% of patients with active disease in a given
year. However, the cumulative relapse rate after 5-years was
already as high as 93.1%. Similar disease course was reported in
a follow-up cohort from the same region in 1991–1993.34
A better disease course was reported in UC during the same
observation period from the Danish group39 in 1161 patients
diagnosed and followed between 1962 and 1987. After the
initial one to two years, approximately 50% of UC patients
were in remission in each year of follow-up, while the
proportion of patients with active disease fell gradually to
about 30% parallel with an increasing proportion of patients
treated by colectomy. The proportion of patients in remission
increased with increasing disease duration. The cumulative
probability of clinical relapse was 81.6% after 5-years' disease
duration, while only 1% of patients experienced continuously
active disease. Interestingly, in the 1991–1993 Copenhagen
cohort34 the probability of aggressive disease during the first
5-years fell from 23.8% to 13.2%.
Somewhat different rates were published in the EC-IBD
study.40 First all types of cumulative recurrence rateswere 34%,
69.2%, and 77.5% after 1, 5, and 10 years of follow-up in 358 CD
patients, with similar second and third all type relapse rates
(40.2%, 76.9% and 82.6% vs. 45.9 and 76.4% after 1, 5, and
10 years). Upper gastrointestinal location and 5-ASA therapy
were associated with increased risk of relapses. Interestingly,
relapse rates were associated to the geographic region. Higher
relapse rates were reported from Copenhagen, while lower
rates were observed in Greece, Italy and Norway. Relapse rates
and disease course were reportedmore recently from the IBSEN
group from Norway.37 Of the 454 UC patients, 78% experienced
at least one relapse during the first 5-years. Relapse rates were
higher in females (p=0.01) and relapsing patients were younger
(pb0.001), but it was not associated to disease extent. In
addition, when patients were asked to self-assess their disease
course, 59% experienced a decline in the severity of intestinal
symptoms during the follow-up period. In contrast, only 1% of
patients experienced an increase in severity, while chronic
continuous symptoms were present in 9%. A relapsing course
was observed in 31%, respectively. In a follow-up study of the
same cohort,41 48% of the UC patients were in clinical remission
between 5 and 10-years after diagnosis.
Similar to earlier reports, a high cumulative relapse rate
(53%, 85% and 90% after 1, 5, and 10 years) was reported in 237
CD patients from the same group33 associated with early needfor steroids but not with disease phenotype or smoking habits.
In contrast, approximately 44% of patients were in clinical
remission during the second 5-year period and 43% experi-
enced a decrease in the severity of disease (according to
predefined disease patterns), during the follow-up period. In
contrast, 3% patients experienced an increase in severity, 19%
experienced chronic continuous symptoms, and 32% experi-
enced a relapsing course.4. Hospitalization rates
Relatively little data are available and hospitalization rates
in patients with IBD vary between European countries. In the
early era a significant proportion of the diagnostic workup
was done on an inpatient basis leading to fairly high initial
hospitalization rates as reported from the Nordic countries.
As an example the hospitalization rate within the year of
diagnosis was as high as 83% in CD patients diagnosed
between 1962 and 1987 in Copenhagen County, Denmark. In
addition, approximately 20% of patients were admitted
yearly over the next 5 years42 (Table 3).
Additional data are available from a Pan-European
prospective follow-up study.43 Data from this study confirm
that hospitalization rates decline significantly from the
second year after diagnosis. The cumulative risk of overall
hospitalization was 52.7% at 10 years from diagnosis, but
with considerable differences between countries. Rates
were highest in Denmark, Ireland, Portugal while low rates
were observed in Norway, Greece and Italy.
In contrast, in UC hospitalization reflects mainly the
failure of medical therapy and disease severity and is
associated with the need for colectomy and ultimately
mortality. In a retrospective cohort from Oxford cohort,
need for hospitalization for acute severe colitis was the most
important predictor for colectomy.44 Overall, 12% needed
colectomy, however the rate was higher, 39.8% (74/186) in
patients with one or more severe episodes compared to
those not needing an admission 3.4% (19/564). Colectomy
rates were increasing with subsequent admission, being
19.9%, 29.0%, and 36.6%% after one, two or three episodes,
respectively. Similar findings were reported from North
America with stable hospitalization rates in UC.45,46
A meta-analysis of hospitalization rates in IBDwas published
from 9 European countries based on the data of the national
statistic offices in 2009.47 Hospitalization rates varied signifi-
cantly among countries between 1.2 and 4.3 discharges per
10,000 for CD and between 0.7 and 4.7 discharges per 10,000
for UC. The highest rates were found in Denmark and Scotland,
while the lowest in Spain, Switzerland and the Netherlands.
Numbers were similar for UC and CD in the given country with a
Table 3 Hospitalization rates in selected European cohorts in patients with Crohn's disease.
Country Time period Cohort type Cohort size Hospitalization rate
Copenhagen, Denmark42 1962–1987 Population-based cohort 373 83% in the 1st year after the diagnosis
and 20% annually in the next 5 yrs.
EC-IBD43 1991–2001 Inception cohort study
from referral centers
425 52.7% in the first 10-years, significant
variation among countries
327Burden of IBD – EpiComspecific age-distribution pattern (CD: high peak in younger
patients and small peak in the elderly. UC: opposite trend).
Nevertheless hospitalization is an important but partly
subjective outcome measure. Need for hospitalization may
be associated to multiple factors including not only disease
severity but also need for diagnostic workup, health care/
reimbursement policy and ethnic differences. Furthermore,
the bar for hospitalization may be different in expert centers
versus community settings.Hospitalization rates are high, but slowly decreasing in
patientswith Crohn's diseasewith approximately 50%
of European patients requiring hospitalization within
10-years from diagnosis. The actual rates may vary
significantly between countries.
In UC, hospitalization rates remained stable and reflect
disease severity and risk for colectomy.5. Surgery in IBD in Europe: rates, trends
and causes
The overall cumulative surgery rates in CD were 10–35%,
21–59% and 37–61% at 1, 5 and 10 years after diagnosis,48
respectively. In general, surgery rates seem to have declined
in the last two decades, as suggested by a recent review
article by Bernstein et al.48 focusing on surgery patterns and
rates published in population-based studies. Surgical rates and
risk for surgery in IBD in Europe are mainly comparable to that
reported from Northern America in both CD and UC with some
exceptions. Of note, the reported surgical pattern naturally
varies between population-based studies and referral centers.
In addition, there are some local geographic differences,
e.g. higher surgical rates are still reported from Denmark or
the lower colectomy rates in UC in the Mediterranean and
Eastern Europe (Table 4).
Early studies reported exceedingly high surgical rates,
such as the population-based Stockholm County cohort from
1955 to 1974. Reported surgery rates were 30%, 50% and 60%
at 5, 10 and 15 years49 and surgical rates did not change
significantly in an update report from a follow-up cohort.50
Similar high rates were reported from Copenhagen in a
population-based cohort some years later (1962–87).51 35%
of CD patients had surgery during the first year after
diagnosis. The cumulative probability of surgery was 61% at
10 years and 82% at 20 years. Similarly, high initial surgical
rates were reported from a referral-based French cohort,
with a need for early surgery as high as 15% in the first three
months after the diagnosis, while the annual surgical ratesremained stable over time (1978–2002).52 In a more recent
update from the Copenhagen cohort significantly lower (12%)
surgery rates were reported within the year of diagnosis in
incident cases diagnosed between 2003 and 20055 and the risk
has continued to decline.53
The latest data from Denmark approach the low surgery
rates reported from another Nordic country, in a population-
based cohort from Southeastern Norway by the IBSEN group
in patients diagnosed between 1990 and 1994. Cumulative
probability of surgery was 14%, 27% and 38% at 1, 5 and
10 years from diagnosis with 9% having at least one
reoperation.33 Terminal ileal location, stricturing or pene-
trating disease and an age younger than 40 years at diagnosis
were significantly associated to the risk for surgery.
The best data outside of the Nordic countries comes from
the multicenter European EC-IBD inception cohort in
patients diagnosed between 1991 and 1993.43 The cumula-
tive surgery rate after 10-years was 37.2%. After the first
surgery, 2.2%, 18.5%, and 35.9% of patients need additional
surgical intervention at 1, 5, and 10 years, respectively.40
Interestingly, a geographic variability was reported. Patients
from Northern European centers, especially Copenhagen,
had higher risk of surgical interventions. The reason for the
observed geographic differences is not well understood.
Partially, this was may be explained by more aggressive
disease phenotype as suggested by the authors but likely
other factors may contribute such as s different attitude
toward surgery.
More recently, declining surgical rates associated with
increased and earlier use of immunosuppressives was
reported from two population-based studies from Cardiff
(Wales) between 1986 and 2003 and Hungary54 between
1977 and 2008. In the first study surgery rates decreased
during the follow-up periods from 59% to 25% 5-years after
the diagnosis (p=0.001) in patients diagnosed in 1986–91and
1998–2003. In the Eastern European study surgical rates
were decreased in patients diagnosed after 1999. The
reported surgical rates were 9.8%, 18.5%, and 21.3% after
1, 3, and 5 years after the diagnosis in patients diagnosed
between 2002 and 2006.24 Also in Denmark, the decrease in
surgery was paralleled with an increasing use of immuno-
suppressives and biologicals, although causality was not
established.53
Unquestionably, the reason for recent decreases in surgery
rates is multifactorial. Disease phenotypes (behavior) in the
more recent cohorts seems to be more mild, with a greater
proportion of patients with inflammatory disease at diagno-
sis,55,56 however other factors are likely to contribute. Follow-
up strategy has changed significantly in the last decades and
increased and earlier use of immunosuppressives may partially
be regarded as a marker (one factor) of this complex change
Table 4 Surgery and colectomy rates in selected European inflammatory bowel disease cohorts.
Country Time period Cohort type Cohort size Surgery in Crohn's disease/colectomy
in ulcerative colitis
1 year 5 years 10 years
Crohn's disease
Sweden49 1955–1974 Population-based cohort 826 – 30% 50%
Denmark5,51 1962–1993
2003–2005
Population-based cohort 373
562
35%
12%
– 61%
Norway33 1990–2000 Population-based cohort 237 14% 27% 38%
EC-IBD43 1991–2001 Inception cohort study
from referral centers
425 – – 37%
UK55 1986–1991 Population-based cohort 105 32% 59% –
1992–1997 99 25% 37%
1998–2003 137 19% 25%
Hungary24,61 1977–2008 Population-based cohort 506 15% 31% 52%
2002–2006 163 10% 21%
Ulcerative colitis
Denmark39 1962–1987 Population-based cohort 1151 – – 24%
Norway41 1990–2004 Population-based cohort 519 3.5% – 9.8%
EC-IBD60 1991–2003 Inception cohort study
from referral centers
771 – – 8.7%
Hungary24,61 1977–2008 Population-based cohort 914 – 1.6% 3.7%
2002–2006 220 0.5% 1.8% 2.8%
328 J. Burisch et al.pointing towards improved medical management. This is
further supported by a recent publication from Canada,57
where authors were able to show an association between early
gastroenterologist care and lower risk of surgery parallel with
an increased early use of immunosupressives. Yet, exposure to
immunosupressives seems to be still relatively low in the
population-based studies and reoperation rates are essentially
unchanged. Of note, the above surgery rates and trends were
reported in mainly pre-biological cohorts with only minimal or
no biological exposure, except for the recent Danish study
which did not report causality.53 Whether biological therapy
directly influences long-term surgery rates and surgery trends
remains unclear.
While the main aim of surgery in Crohn's disease is to
eliminate the complications, the indication of colectomy
and surgical therapy in ulcerative colitis is usually failure of
medical therapy leading to chronic active disease or
fulminate colitis. In one of the early studies from Sweden,
excessive colectomy rates (20% and 45% at 5 years and
25 years) were reported in 1586 patients followed-up from
1955 to 1984.58 Disease extent was universally identified as
an important predictive factor for colectomy. Interestingly,
a disease extension was observed in the majority of the
patients with initial proctitis who needed colectomy later
during the disease course. Similarly, high colectomy rates
were reported from the Copenhagen59 county in the same
time period with 10% of patients requiring colectomy in the
year of diagnosis.
Higher colectomy rates were persistently reported from
the Northern-European centers, as confirmed also in the
more recent EC-IBD study in patients diagnosed between
1991 and 1993.56,60 Of note, the cumulative colectomy ratewas lower (8.7%) compared to the previously reported rates.
Nonetheless, the difference between northern and southern
centers was significant with 25.7% 10-year cumulative
colectomy risk from Denmark (HR 8.2; 95% CI, 3.6–18.6),
8.2% from Norway and the Netherlands combined (HR 2.7;
95% CI, 1.3–5.6) and only 3.9% from the south European
centers. Similarly low overall colectomy rates were reported
in population-based studies from Eastern Europe. The
cumulative colectomy rate was 1.6% and 3.7% after 5 and
10 years' disease duration in UC patients diagnosed between
1977 and 2008.61
Finally, new data from the Nordic countries are showing
a trend for decreasing colectomy rates. A prospective
population-based study in the early 1990s from South-eastern
Norway by the IBSEN group41 revealed 3.5% and 10% colectomy
rates at 1 and 10-years after the diagnosis. Similarly, lower
colectomy rates were recently reported from Denmark5 with a
10 year colectomy rate of approximately 10%.40
Of note, higher colectomy rates were reported from
studies done in solely pediatric onset UC populations from
Northern and Western Europe. In a Danish population-based
study the cumulative colectomy rate in the pediatric-onset
UC patients diagnosed between 1962 and 1987 was 6.4%,
26%, and 29% at 1, 10, and 20 years.62 Colectomy rates were
similar in a recent population-based French study.63 The
cumulative rate of colectomy was 8%, 15% and 20% after 1, 3,
and 5 years' disease duration. Interestingly, the presence of
extra intestinal manifestations (7% at diagnosis and 22%
cumulatively) increased the risk for colectomy (HR 3.5; 95%
1.2–10.5).
It is not clear why colectomy rates are lower in southern
and Eastern Europe. Of note however, disease severity
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acute severe colitis) is not necessarily milder in southern or
Eastern European centers.The overall cumulative surgery and reoperation rates in
Crohn's disease are still high in Europe with 30–50%
of patients needing a surgical intervention and up to
20% needing a reoperation after 5–10 years from the
diagnosis according to population-based data. Recent
data indicate a decrease in the surgical rates.
The risk of colectomy in ulcerative is approximately
10% after 10 years from the diagnosis. The un-
explained geographic variation in the colectomy
rates between northwest and Southeast Europe is
diminishing in recent years.
In European studies, EIMs were present in as high as6. Extra intestinal manifestations
IBD is associated with a large number of extra intestinal
manifestations (EIM). In European studies, EIMs were present
in as high as 20–40% of patients with CD and app. 15–20% of
patients with UC.64 In general EIMs are more common in
females. The prevalence is increasing during follow-up, e.g. in
a Hungarian study the frequency was higher in patients with a
disease N10 years in both CD (29.9% vs. 48.9%, p=0.003) and
UC (22.1% vs. 10.4%, pb0.001).64
Joint manifestations (peripheral or axial arthropathies)
are the most common EIM in IBD, and occur in 20%–30% of
patients during follow-up in studies from Hungary, Italy,
Switzerland and UK.64,65 Symptom range is relatively broad
from non-inflammatory arthralgia to acute arthritis with
painful swollen joints. In an Italian prospective one-year
follow-up study66 of 651 IBD patients 45.1% of CD and 36.9%
of UC patients reported past or present articular symptoms
during a median follow-up of 11 years. In 46% this was
associated with active IBD, in 56% symptoms were intermit-
tent and in 19% symptoms preceded IBD diagnosis, while
9.5% of patients (CD: 12.8% and UC: 7.2%) reported recent
articular symptoms over the one-year prospective follow-up
period.
Peripheral arthropathies can be divided into two sub-
groups as suggested by authors from the UK67: type 1
arthritis (an acute, self-limiting, pauciarticular (N5 joints)
arthropathy, typically affecting large joints, associated with
other EIM and its course parallels the activity of intestinal
disease); and type 2 arthritis (a chronic, bilateral, symmet-
rical, polyarticular arthropathy affecting five or more small
joints, its course runs independent to the course of intestinal
disease with a prevalence of 2–4% in both CD and UC). In
previous studies from Hungary and the UK, cumulative
prevalence of arthritis was more common in CD compared
to UC (axial 10% vs. 3% and type-1 6–11% versus 2.7–3.6%), in
women and in colonic disease.64,67
Axial arthropathies are sacroileitis and ankylosing spon-
dylitis (AS) with a cumulative incidence of 2–6% in IBD
(20-fold higher than in the normal population).64,65,68 In
addition, arthriticular manifestations may be more frequent
in CD patients with stenosing/penetrating disease and in UC
in patients with pancolitis. Peripheral but not axial arthritiswas more frequent in CD patients with an active disease in
the Swiss IBD cohort (45.1% vs 31.3%, p=0.01).65 In contrast,
no difference in arthritis frequency was reported in UC
patients with an active disease or in remission.
Erythema nodosum (EN), pyoderma gangraenosum (PG),
and aphthous stomatitis are the most common cutaneous
manifestations in IBD. Prevalence rates reported from
France, Hungary, Switzerland and UK are app. 5–15% in CD
patients, with female predominance, paralleling disease
activity in up to 92% of episodes and may recur in app. 20–
30% of patients.64,65,69,70 EN is less common in UC (2–10%),
however, the frequency may be higher in patients with
extensive colitis. The frequency of PG is less common in both
CD and UC (1–2%). In contrast, 36%–50% of patients with PG
suffer from IBD. Aphthous stomatitis may be present in 1–
10% of IBD patients. The course of skin manifestations is
usually related to disease activity but sometimes, especially
in the case of pyoderma gangrenosum, may take an
independent course. Interestingly, in the Swiss IBD cohorts,
only the frequency of aphthous stomatitis was linked to
disease activity in patients with CD (17.1% vs 8.6%, p=
0.026).65 Finally, in a large French referral cohort patients'
skin manifestations were diagnosed in 5.8% in 2402 IBD
patients (5.6% EN and 0.75% PG).70 Of note, the median
delay between the IBD diagnosis and the occurrence of the
first dermatologic manifestation was 3.9 years, with a trend
for an earlier occurrence in CD patients (CD: 3.5 vs. UC:
5.9 yr, p=0.13) for EN, but not for PG.
The most common ocular manifestations include uveitis
and episcleritis. Their prevalence is between 3 and 6% in both
CD and UC in studies fromHungary, Switzerland and UK.64,65,69
They are associated with disease activity in up to 78% of
episodes, with recurrent episodes in app. 30% of patients.69 In
the Swiss IBD cohort, the frequency of uveitis was 2-fold higher
in patients with active CD (12.2 vs. 5.2%), but an association
was not found in UC.65 In a Hungarian population-based
cohort,64 ocular manifestations were associated with the
disease extent in UC (6.1% in pancolitis vs 1.9% in left sided
colitis or proctitis, p=0.01). Furthermore, ocular manifesta-
tions may frequently occur together with other (joint or
cutaneous) EIM.64,69,70
PSC may be present in 0.7–2% patients with CD and 2–4%
of UC patients in studies from both Western and Eastern
Europe.64,65 If small-duct PSC is included, the overall
prevalence ranges between 2.4 and 11%.64,7120–40% of patients with CD and 15–20% of patients
with UC.7. Disability and economic burden of IBD
in Europe
Little data are available on disability in patients with IBD.
Unfortunately, an unequivocal definition of disability is
difficult and available assessment tools are measuring
different aspects of disability. In one of the early publica-
tions by Sonnenberg72 CD and UC led to disability in
significantly younger patients than other diseases with a
significant socioeconomic impact. In CD disability was more
330 J. Burisch et al.common in females, while disability from UC was similar in
both sexes.
A second German study reported in 1992 that each year,
about 9% and 3% of all German employees with IBD
underwent a rehabilitation or were granted a disability
pension and that, although they had significantly longer sick
leaves, 87% were still employed before entering rehabilita-
tion.73 Importantly, 64% of the total social costs in CD were
indirect costs such as early retirement or sick leave, while in
UC this was estimated to be as high as 54%.74
Of note, however, a huge variation was reported in the
disability rates across the world. The TREAT registry
reported an overall disability rate of 25%, ranging from 20%
in the US to 34% in Europe,75 possibly reflecting differences
in disease severity, local socioeconomic and societal factors,
and insurance policies. In 2008 Timmer76 summarized data in
IBD patients on sick leave in the pre-biologics era. It is
estimated that an IBD patient will be sick about 4 weeks per
year, off from work for 3 to 6 weeks per year and
hospitalized for 10 days. In concordance, IBD patients from
the UK77 reported significant interference with social
activities, irrespective of the severity of the disease or
disease subtype. Median days lost from “household and
recreational activities” in six months was 17 in patients with
UC and 20 in patients with CD. It should be noted that
hospitalization rates may depend on local healthcare policies
and are, therefore, difficult to compare across Europe.
In early studies, high disability pension rates were reported
from Copenhagen (15% after 15 years' disease duration) in
patients with CD.42 In a more recent study performed on the
IBSEN cohort after 5-year disease duration,78 unemployment
(11.7%) and sick leave (app. 50%) were more common in IBD
patients compared to the Norwegian background population.
In contrast, the disability pension rate was only increased in
females with CD, confirming earlier data from Germany.73
These results are in linewith the results of amore recent study
performed in the IBSEN cohort of patients where CD had higher
impact on health related quality of life (HRQOL) compared
with UC.79 Further, women with CD had worse outcome than
men in subjective health status and had higher rates of
sickness, disability pension and single living.80
Also, in the recent update of the IBSEN cohort, the overall
disability pension rate 10 years after diagnosis of IBD was 18.8%
with significantly elevated RRs of 1.8 in UC and 2.0 in CD. The
relative risk for disability pension was highest in patients below
40 years at diagnosis.81 In addition, a recent Dutch study has
shown that although IBD patients are as often employed as the
general population, fewer people work fulltime.82
A recent European survey,83 presented by the European
Federation of Crohn's & Ulcerative Colitis Associations (EFCCA)
in partnership with the European Crohn's and Colitis Organi-
zation (ECCO), assessed burden of IBD in Europe through
patients' reported data. Underemployment and unemploy-
ment due to the intestinal disease were reported in,
respectively, 10% and 8% of IBD patients (2/3 in CD). Chronic
disease activity was related to both under/unemployment and
disability retirement. About half of the patients responded
that that their life was significantly affected by IBD during
their most recent flare-up. Of these, 26% had had more than
25 days of absence due to IBD and 56% of underemployed
respondents worked only part-time. IBD also affects working
behavior and career path. 44% of respondents said that theyhad lost or had had to quit a job because of IBD and 52% felt
that IBD had negatively affected their education. Interesting-
ly, Hoivik et al.84 reported that work status and sick leave
were the only variables, besides IBD related symptoms, that
negatively affected HRQOL.
As mentioned initially, comparison between studies and
populations is difficult due to underlying differences in
definition of disability and in societies. However, recently, a
comprehensive International Classification of Functioning,
Disability, and Health (ICF) core set for capturing specific
aspects of disability in IBD has been published, and this may
lead to a more uniform and objective assessment of disability
in patients in IBD.85 Finally, it is difficult to measure the
economic burden of the disease in the different European
countries given the large variation in direct and indirect costs
and significant differences in the health care policies. Most
systematic data are available from North America.86,87 Studies
from Europe were published only in the last decade. German
and English authors reported retrospectively the inpatient and
outpatient costs, from the payer perspective in Ulm
and Liverpool.77,88 In year 2000, the cost for treating CD was
₤3416 per patient-year, and for UC, ₤3021 per patient-year.
Inpatient and surgery costs accounted for over half of the
costs, and the 10%most costly patients in CD andUC accounted
for 59% and 62% of total costs. Patients requiring hospitalization
had 10-fold higher costs compared to patients not hospitalized.
Similar datawere reported in Germany in 1997–2000. Themean
cost for outpatient care was €3171 per patient-year in all 548
patients, with drugs accounting for 85% of the total costs. Costs
were no different between patients with CD or UC.
The cost analysis from the EC-IBD inception cohort43 was
published in 2006. 425 CD patients and 896 UC patients were
included in the analysis of eight European countries and
Israel. The mean total health care cost (outpatient care,
diagnostics, hospitalization, surgery, medication) in IBD was
€1871 (SD €4884) per patient-year over the 10-year follow-up.
The costs were higher for CD (€2548 per patient-year)
compared to UC (€1524 per patient-year). Mean costs varied
considerably between countries, being highest in Denmark at
€3705 per patient-year and lowest in Norway at €888 per
patient-year. Hospitalization accounted for 63% of the cost in
CD and 45% in UC. Total and hospitalization costs were much
higher in the first year after diagnosis than in the follow-up
period. Interestingly, 5-aminosalicylic acid (5-ASA) derivatives
were the most expensive drug category, however this was a
mainly pre-biologic cohort with long-term 5-ASA use. The
extent of disease was found to affect the cost in UC patients
only. In contrast, in CD the costs varied significantly according
to the Vienna classification phenotypes.
In a more recent publication89 from the same cohort mean
costs were analyzed over the 10-year follow-up period per
3-month treatment cycles from 13 centers. The costs for all
treatment states were higher in CD with the exception of
surgery. Mean costs were highest for the surgical cycles in both
UC and CD (€8132/cycle and €6998/cycle), followed by
drug-responsive and drug-dependent states (UC: €1760 and
€839/cycle; CD: €2029 and €1033/cycle). Not surprisingly, the
costs for mild disease or medical remission were the lowest
(UC: €104 and €274/cycle; CD: €184 and €316/cycle). Far more
economic studies will be needed in the future to assess the
long-term cost-effectiveness and cost-utility of the more
intense patient monitoring and advanced treatment strategy
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treatment strategy from the pre-biologic data, the direct
economic burden associated with IBD can be estimated as high
as a total of 4,681–5,596 million Euro direct costs per year in
Europe. Updated cost estimation models based on new
treatment algorhythms long term, incorporating the biological
therapies are urgently awaited.The health economic burden and permanent work
disability in IBD are high in Europe with a total yearly
direct healthcare cost of 4.6–5.6 bn Euros.
Unemployment (10%), sick leave (3–6 weeks/year),
and permanent work disability (2-fold increased) are
more common in patients with IBD than in unaffected
individuals. The economic impact is even higher since
IBD is affecting patients at an early age.
The risk of colorectal cancer in European patients with
Crohn's disease is close to that of the general
population.
The relative risk of small bowel cancer in European
patients with Crohn's disease is several fold increased,
but it is in general a very rare disease and the absolute
risk is low.
The risk of colorectal cancer in European patients with
ulcerative colitis has been twice as high as that of the
general population.
However, the absolute risk is only 1–2.5% at 20 years8. Cancer and mortality
The earliest studies on risk of cancer and mortality in
patients with IBD primarily came from the US and to some
extent Europe and tended to be based on highly selected
patient populations referred for specialist care at tertiary
centers.90–92 This may be the reason why risk estimates
were worryingly high and may have resulted in wrong
information of patients and impaired possibilities to obtain
reasonably priced medical and life insurances.93
Prognostic studies should ideally be based on unselected
patient cohorts representing the broad range of disease
appearance and hence producing results that are generalizable
to the average IBD patient. This was recognized by Truelove
and colleagues in Oxford, UK, in the 1960s and 1970s, where
the group published the first important observations of a much
better prognosis in ‘new cases’ with IBD (i.e. those diagnosed
and followed at the same clinic) as compared to ‘referred
cases’.94 Following this work, a number of population-based
Scandinavian studies were published, which also spoke against
a markedly increased risk of cancer or mortality, although the
risk of colorectal cancer in patients with extensive colitis was
not negligible in all studies.95–106
Results on prognosis from population-based studies have
been collected in meta-analyses during the last decade and in
addition to these, cross-European and Eastern European
studies have emerged in recent years. These will be summa-
rized in the following.
8.1. Colorectal and small bowel cancer
In year 2006, a meta-analysis was published on risk of intestinal
cancer in population-based cohorts of patients with Crohn's
disease. The meta-analysis was based on 6 studies, of which 4
were European, and the pooled standardized incidence ratio
(SIR) of colorectal cancer was 1.9 (95% CI, 1.4–2.5), whereas
the SIR of small bowel cancer was 27.1 (95% CI, 14.9–49.2).107
Of note, the latter estimate was based on very few cases (i.e. a
very low absolute risk), which only resulted in a 27-fold
increased relative risk due to the extremely rare occurrence
of small bowel cancer in the general population. When later
adding an Italian study to the meta-analysis, nearly identical
estimates were obtained.108 However, the increased risk ofespecially colorectal cancer in patients with Crohn's disease
was to some extent explained by the high risk observed in a
large Canadian study,109 which provided the largest weight to
themeta-analysis, whereas studies fromDenmark (1962–1997),
Sweden (1955–1984; 1965–1983) and Israel (1970–1980) reported
quite low SIRs of 1.14 (95% CI, 0.31–2.92), 0.89 (95% CI, 0.29–
2.07), 2.2 (95% CI, 1.0–4.3), and 1.14 (95% CI, 0.03–6.33).107 In
linewith this, a recent nationwide Danish cohort study showed no
increased risk of colorectal cancer among patients with Crohn's
disease,110 and this was also the case in a study from Hungary of
501 incident CD patients (SIR, 0.99; 95% CI, 0.41–2.39).The risk of colorectal cancer in ulcerative colitis has in a
former meta-analysis including highly selected studies
been suggested to be markedly increased with cumulative
probabilities of 2% by 10 years, 8% by 20 years, and 18% by
30 years.111 However, a recent meta-analysis based ex-
plicitly on population-based studies (8 studies of which 6
were European and the majority Scandinavian) revealed a
pooled SIR of 2.4 (2.1–2.7) which was based on relatively
low absolute numbers with a cumulative incidence of CRC
of less than 1% at 10 years, 0.4%–2.0% at 15 years, and of
only 1.1–2.5% at 20 years in studies with sufficiently long
follow-up time.112 In accordance with this finding, a recent
Hungarian cohort study reported that the relative risk of
CRC after a median follow-up time of 10 years was only
1.74 (95% CI, 1.01–3.0) despite a higher frequency of
extensive disease and lower surgery rates in Eastern
European countries than in Northern Europe.113 Further,
recent cohort studies from Sweden114 and Denmark110 have
suggested that the risk of CRC in UC has decreased over
calendar time, and that the risk of CRC today is confined to a
subset of patients with extensive/long-standing disease,
primary sclerosing cholangitis and young age at diagnosis.and Scandinavian studies suggest a decrease in risk in
recent years.8.2. Extra-intestinal cancer
A meta-analysis from year 2010 on extra-intestinal malig-
nancy in 8 population-based IBD cohort studies (of which 6
were European: 3 from Sweden, 1 from Denmark, 1 from
Italy and 1 based on the EC-IBD cohort) revealed that the
overall risk of extra-intestinal cancer was not increased (SIR,
1.10; 95% CI, 0.96–1.27).115 However, patients with CD were
still at increased risk of cancer of the upper gastrointestinal
tract (SIR, 2.87; 95% CI, 1.66–4.96), lung (SIR; 1.82; 95% CI,
Mortality is up to 40% increased in European patients
with Crohn's disease as compared to the general
population.
332 J. Burisch et al.1.18–2.81), urinary bladder (SIR, 2.03; 95% CI, 1.14–3.63), and
skin (SIR, 2.35; 95% CI, 1.43–3.86), whereas UC patients had an
increased risk of liver-biliary cancer (SIR, 2.58; 95% CI, 1.58–
4.22) and leukemia (SIR, 2.00; 95% CI, 1.31–3.06), which was
counterweighted by a decreased risk of pulmonary cancer (SIR,
0.39; 95% CI, 0.20–0.74).115 These findingsmay to some extent
reflect differences in smoking habits between CD and UC
patients, whereas the effect of IBD itself and the treatment
hereof on risk of extra-intestinal cancer may have changed
with changing treatment options, as the majority of included
studies were several decades old. Especially, the risk of skin
cancer and lymphoma in IBD has been debated following the
introduction of thiopurines116–119 and biologicals,120 but it is
difficult to differentiate between an increased baseline risk
and an increased risk related to drug exposure.121 Concerning
the risk of lymphoma, a recent Hungarian study of 1420
patients followed for 19,293 person-years observed 3 lympho-
mas, all occurring in patients who had never received
thiopurines or biologicals and the risk was not higher than
among non-IBD individuals (SIR, 1.37; 95% CI, 0.44–4.26).122 In
contrast, a study from the French CESAME cohort (n=19,486
IBD patients) found a multivariate-adjusted hazard ratio of
lymphoproliferative disorder of 5.28 (2.01–13.9, p=0.0007)
when comparing patients receiving thiopurines with patients
who had never received these drugs.117 However, the French
study may have been influenced by selection bias and a recent
unselected nationwide Danish cohort study of 45,986 patients
with inflammatory bowel disease (1997–2008) reported amore
modestly increased risk of lymphoid tissue cancer in IBD
patients using thiopurines (RR, 2.40; 95% CI, 1.13–5.11)
when compared to unexposed IBD patients and adjusting
for propensity scores and a number of potential con-
founders.123 In line with this, a General Practice Research
Database study in the UK reported an OR of 3.22 (95% CI,
1.01–10.18) for lymphoma in ever users of azathioprine as
compared to non-users.118 A Dutch study pathology register
study of 17,834 IBD patients found no overall increased risk of
lymphoma in IBD, but suggested an association between AZA/
6-MP use and EBV-positive lymphoma.124 The risk of cancer
following treatment with biologicals still needs to be investi-
gated in long-term observational studies, as done in a recent
Danish nationwide cohort study suggesting no overall increased
risk of cancer in anti-TNF-α exposed IBD patients compared to
unexposed patients.125
Finally, the 15-year follow-up of the EC-IBD cohort
suggested no increased overall risk of cancer among patients
with IBD (independent of treatment).126The overall risk of extra-intestinal cancer is not
markedly increased in European patients with IBD
despite an increased risk of cancer of the upper
gastrointestinal tract, lung, skin and urinary bladder in
Crohn's disease and an increased risk of biliary-liver
cancer and leukemia in UC counterweighted by a
decreased risk of lung cancer.
Thiopurines may increase the risk of lymphoid tissue
cancer and non-melanoma skin cancer among European
IBD patients, but drug effects are to some extent
difficult to differentiate from the baseline increased risk
of these cancers.8.3. Mortality
In a meta-analysis from year 2010 on mortality in CD based on 9
population-based studies of which 8 were European (including
an EC-IBD study), the pooled SMR was 1.39 (95% CI, 1.30–1.49).
Mortality was increased from cancer, chronic obstructive
pulmonary disease, gastrointestinal disease, and genitourinary
disease.127 A recent nationwide Danish study onmortality in IBD
confirmed a 50% increasedmortality in CDwhich did, in contrast
to what was observed for UC, not decrease over time, hence
suggesting that changes in treatment have not improved
survival.128 However, in contrast to the 40–50% increased
mortality in the majority of former studies, a population-based
cohort study from Finland (1986–2007) of 1915 adult IBD
patients showed no increased mortality from CD. This may be
due to the fact that an increased mortality from diseases of the
digestive system was counterweighted by reduced mortality
from mental and alcohol-related behavioral disorders when
comparing IBD patients to the general Finnish population.129
Still, another recent population-based study (Netherlands;
1991–2003) also questioned the suggested increased mortality
from CD (SMR, 1.1; 95% CI, 0.7–1.6), despite a significantly
increased mortality from gastrointestinal causes (SMR, 7.5; 95%
CI, 2.8–16.4) in this patient group.130In a meta-analysis from year 2007 on mortality in UC based
on 10 population-based studies (8 European including EC-IBD)
no increased overall mortality was observed (standardized
mortality ratio, SMR, 1.1; 95% CI, 0.9–1.2), although an excess
mortality was seen in patients with extensive colitis, in the
first years after diagnosis and in Scandinavian patients.131 In
particular, increased mortality from gastrointestinal diseases,
non-alcoholic liver diseases, pulmonary embolisms, and
respiratory disease (pneumonia) was observed, but this was
counterweighted by reduced mortality from pulmonary
cancer.42 The studies of the meta-analysis were, however,
not recent and a more recent nationwide Danish study reports
a decreasing overall mortality among patients with UC during
the last three decades, primarily explained by decreased
mortality from CRC.128 A decrease in mortality from CRC
among patients with UC was also observed in a recent Swedish
study,114 whereas a recent population-based Dutch study
showed decreased mortality from overall cancer in UC.130
Population-based studies on mortality among IBD patients
from Eastern Europe are lacking.Mortality is not increased in European patients with
ulcerative colitis as compared to the general population.9. Summary and conclusion
In conclusion, the incidence and prevalence of IBD have
increased in the last few decades throughout Europe. The
current estimated prevalence of IBD is approximately 0.3%
333Burden of IBD – EpiComof the European population with a significant geographic
variation (North/West to South/East gradient). Studies are
underway (e.g. ECCO EpiCom initiative) to further explore
the factors associated and responsible for these trends.
Since IBDs affect mainly young individuals in their early
adulthood and impact all aspect of the affected individual's life
they account for substantial direct and indirect costs to both
health care system and society. There seems to be a change in
the natural history of IBDs as suggested by the recent studies.
However, about half of the patients have frequent relapses or
continuous active disease and may develop extra intestinal
manifestations. In addition up to 2/3 of the patients with CD
patients still develop complications requiring hospitalization
and/or surgery although some recent studies suggest a
decrease in the surgical rates. Surgical rates have also
decreased in UC with 10–15% of patients ultimately requiring
colectomy. However, there is an unexplained geographic
variation in the colectomy rates between north/west and
south/east Europe. The factors reported to be associated with
these changes include an altered patient monitoring (more
complex, tight patient control) and an optimized, tailored
treatment strategy including now a more systematic use of
biologicals. Future studies are needed to determine if these
drugs can further improve long-term disease outcomes.
New data from Europe suggest that the risk of cancers is
lower compared to that previously reported; e.g. the
colorectal cancer is close to that in the general population
in CD and about 2-fold (1–2.5% after 20-years) in UC
according to data from Scandinavia and Hungary. In addition,
the risk of extra intestinal cancers is not markedly increased in
the European patients.
Nonetheless, the long-term disability rate, economic
and social impact of IBD in Europe is enormous. Unfortu-
nately, still app. 20% of the IBD patients in Europe will end
up with disability pension and further 10% and 25% have to
face unemployment or part time employment problems. In
addition sick leave is affecting up to half of the patients
and even direct health care costs may be as high as 2–3000€ in
average. However, a restructuring of the costs is currently
occurring and in a short term study from The Netherlands
anti-TNFs already accounted for as high as 2/3rd of the direct
costs in CD and 1/3rd in UCwith a 3-month total cost of €1626 in
CD and €595 in UC).155 Further Pan-European epidemiological
and follow-up studies as well as strategic disease modifying
trials are needed to investigate the role of tight control and
early patient profile stratification in the disease management
hopefully leading to superior long-term outcomes, improved
quality of life, decreased disability rates and ultimately normal
life.
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